Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Objective criteria for crohn-like lymphoid reaction in colorectal cancer.

Ueno H, Hashiguchi Y, Shimazaki H, Shinto E, Kajiwara Y, Nakanishi K, Kato K, Maekawa K, Miyai K, Nakamura T, Yamamoto J, Hase K.

Am J Clin Pathol. 2013 Apr;139(4):434-41. doi: 10.1309/AJCPWHUEFTGBWKE4.

2.

Comparative validation of assessment criteria for Crohn-like lymphoid reaction in colorectal carcinoma.

Kim JH, Kim KJ, Bae JM, Rhee YY, Cho NY, Lee HS, Kang GH.

J Clin Pathol. 2015 Jan;68(1):22-8. doi: 10.1136/jclinpath-2014-202603. Epub 2014 Oct 16.

PMID:
25322692
3.

Characteristics and significance of colorectal cancer associated lymphoid reaction.

Väyrynen JP, Sajanti SA, Klintrup K, Mäkelä J, Herzig KH, Karttunen TJ, Tuomisto A, Mäkinen MJ.

Int J Cancer. 2014 May 1;134(9):2126-35. doi: 10.1002/ijc.28533. Epub 2013 Oct 24.

4.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J.

J Clin Oncol. 2011 Feb 20;29(6):610-8. doi: 10.1200/JCO.2010.30.5425. Epub 2011 Jan 18.

5.

[Predictive value of intraepithelial (CD3) T-lymphocyte infiltration in resected colorectal cancer].

Borda F, Martínez-Peñuela JM, Borda A, Muñoz-Navas M, Jiménez J, Carretero C.

Gastroenterol Hepatol. 2012 Oct;35(8):541-50. doi: 10.1016/j.gastrohep.2012.05.003. Epub 2012 Aug 2. Spanish.

PMID:
22858112
6.

Prognostic impact of B-cell density in cutaneous melanoma.

Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J, Tímár J.

Cancer Immunol Immunother. 2011 Dec;60(12):1729-38. doi: 10.1007/s00262-011-1071-x. Epub 2011 Jul 21.

PMID:
21779876
7.

Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis.

Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Lab Invest. 2004 Apr;84(4):493-501.

8.

T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases.

Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, DeMatteo RP.

Ann Surg Oncol. 2009 Sep;16(9):2524-30. doi: 10.1245/s10434-009-0585-3. Epub 2009 Jul 1.

PMID:
19568816
9.

Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma.

Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P.

Clin Cancer Res. 2012 Feb 1;18(3):850-7. doi: 10.1158/1078-0432.CCR-10-3186. Epub 2011 Dec 5.

10.

Expression of cell cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma.

Al-Maghrabi J, Al-Ahwal M, Buhmeida A, Syrjänen K, Sibyani A, Emam E, Ghanim A, Al-Qahtani M.

J Gastrointest Cancer. 2012 Jun;43(2):279-87. doi: 10.1007/s12029-011-9292-y.

PMID:
21637966
11.

MLH1 and MSH2 protein immunohistochemistry is useful for detection of hereditary non-polyposis colorectal cancer in young patients.

Paraf F, Gilquin M, Longy M, Gilbert B, Gorry P, Petit B, Labrousse F.

Histopathology. 2001 Sep;39(3):250-8.

PMID:
11532035
12.

Gene expression of the mismatch repair gene MSH2 in primary colorectal cancer.

Jensen LH, Kuramochi H, Crüger DG, Lindebjerg J, Kolvraa S, Danenberg P, Danenberg K, Jakobsen A.

Tumour Biol. 2011 Oct;32(5):977-83. doi: 10.1007/s13277-011-0199-9. Epub 2011 Jul 6.

PMID:
21732224
13.

BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, Church JM.

Dis Colon Rectum. 2012 Feb;55(2):128-33. doi: 10.1097/DCR.0b013e31823c08b3.

PMID:
22228154
14.

Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.

Xi HQ, Zhao P.

J Clin Pathol. 2011 Jun;64(6):498-503. doi: 10.1136/jcp.2010.087213. Epub 2011 Mar 17.

PMID:
21415057
15.

Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma.

Toiyama Y, Miki C, Inoue Y, Minobe S, Urano H, Kusunoki M.

Surg Today. 2010;40(1):46-53. doi: 10.1007/s00595-009-4016-7. Epub 2009 Dec 29.

PMID:
20037839
16.

The value of immunohistochemistry for collagen IV expression in colorectal carcinomas.

Offerhaus GJ, Giardiello FM, Bruijn JA, Stijnen T, Molyvas EN, Fleuren GJ.

Cancer. 1991 Jan 1;67(1):99-105.

17.

Immunohistochemical assessment of lymphovascular invasion in stage I colorectal carcinoma: prognostic relevance and correlation with nodal micrometastases.

Barresi V, Reggiani Bonetti L, Vitarelli E, Di Gregorio C, Ponz de Leon M, Barresi G.

Am J Surg Pathol. 2012 Jan;36(1):66-72. doi: 10.1097/PAS.0b013e31822d3008.

PMID:
21989343
18.

Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer.

Huh JW, Lee JH, Kim HR.

Arch Surg. 2012 Apr;147(4):366-72. doi: 10.1001/archsurg.2012.35.

PMID:
22508783
19.

Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study.

Stender MT, Larsen TB, Sørensen HT, Thorlacius-Ussing O.

J Thromb Haemost. 2012 Oct;10(10):2027-31. doi: 10.1111/j.1538-7836.2012.04887.x.

20.

The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients.

Milasiene V, Stratilatovas E, Norkiene V.

Medicina (Kaunas). 2007;43(7):548-54.

Items per page

Supplemental Content

Write to the Help Desk